Join our daily newsletter At The Bell to receive exclusive market insights
EMVision (ASX:EMV), seeking to disrupt the brain scanner tech space, has sent off a second ‘Emu‘ bedside scanner to a US-based Mayo Clinic site for testing.
Shortly to be put to the test in the Jacksonville, Florida Mayo facility; so too will researchers across the bay at the Memorial Hermann-Texas Medical Centre put it to the test – right now, EMV staffers are arriving at the latter helping with training.
EMVision is attempting to design brain scan products so revolutionary that hospitals and first response teams will have no choice but to snap them up. This approach can be seen behind its brain scanner targeting first responders.
That portable brain scan product, separate from the ‘Emu’ bedside scanner the subject of today’s release, is intended to reach a point where paramedics can scan the brain of a trauma crash victim right there on the spot.
Potentially, that could do away with any risk from driving a patient to hospital first, where more appropriate action might otherwise be needed.
But let’s get back to ‘Emu,’ the bedside version for hospitals. In a similar fashion, it allows for a “walk up and scan” approach to brain imaging, as opposed to having to put patients through gentle and long-winded journeys down to MRI machines and the like.
As part of the EMV team’s boots-on-the-ground trip to Texas, the company’s representatives are also to present at a “the inaugural Novel Treatments for Acute Brain Injury (NABI)” conference in Houston. The event, EMV noted, is “invite-only.”
These activities precede the company’s plans to eventually have its devices tested in medical contexts across Australia.
Despite the news, investors sold of EMV on fairly low volumes with the stock down -0.5% to $1.94/sh at a turnover of $85.K shares.
EMV last traded at $1.94.
Join the discussion: See what HotCopper users are saying about EMV and be part of the conversations that move the markets.
-1200x645-380x200.jpg)